<code id='9794326B41'></code><style id='9794326B41'></style>
    • <acronym id='9794326B41'></acronym>
      <center id='9794326B41'><center id='9794326B41'><tfoot id='9794326B41'></tfoot></center><abbr id='9794326B41'><dir id='9794326B41'><tfoot id='9794326B41'></tfoot><noframes id='9794326B41'>

    • <optgroup id='9794326B41'><strike id='9794326B41'><sup id='9794326B41'></sup></strike><code id='9794326B41'></code></optgroup>
        1. <b id='9794326B41'><label id='9794326B41'><select id='9794326B41'><dt id='9794326B41'><span id='9794326B41'></span></dt></select></label></b><u id='9794326B41'></u>
          <i id='9794326B41'><strike id='9794326B41'><tt id='9794326B41'><pre id='9794326B41'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:knowledge    - browse:974
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus